地诺单抗售价多少一盒呢？

Giant cell tumor of bone is a histologically benign but often aggressive skeletal tumor that mostly occurs in young adults aged 20 to 40 years old. The incidence rate in women is slightly higher than that in men, accounting for about 56.4%. Globally, giant cell tumor of bone accounts for approximately 4%-5% of all primary bone tumors. Compared with European and American populations, it is more common in China, accounting for approximately 20% of all primary bone tumors. Although the vast majority of giant cell tumors of bone are benign tumors, if left untreated, they often cause complete destruction of the affected bone, leading to fractures, joint dysfunction, or amputation. Giant cell tumor of bone is composed of stromal cells expressing RANKL and osteoclast-like giant cells expressing RANK receptors. Its pathogenesis is that overexpression of RANKL causes tumor growth and bone destruction.

RANKL is a transmembrane or soluble protein necessary for the formation, function, and survival of osteoclasts; osteoclasts are responsible for bone resorption, thereby regulating bone calcium release. Denosumab (Denosumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. RANK receptor signaling promotes osteolysis and tumor growth. Desosumab inhibits tumor growth and reduces bone destruction by binding to RANKL and preventing it from activating RANK on the surface of osteoclasts, osteoclast precursors and osteoclast-like giant cells.

On May 27, 2019, Amgen China announced that XGEVA® (English brand name In 2018, denosumab (Denosumab) was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration. This approval makes denosumab (Denosumab) the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

According to the editor of Medical Companion Travel, denosumab (Denosumab) currently on the market in the United States is 60mg/1ml tube/box, priced at US$1,169.98. The price is relatively expensive, and most families of patients with average economic levels cannot afford the high medical expenses. Fortunately, denosumab (Denosumab) produced by the American company Amgen has been launched in Turkey. The specification is 125mg/1ml tube/box, and the price is equivalent to RMB 3,000, which can be said to be high quality and low price.